NASDAQ:AUTL Autolus Therapeutics (AUTL) Stock Price, News & Analysis $1.62 +0.04 (+2.20%) Closing price 06/26/2026 03:59 PM EasternExtended Trading$1.60 -0.02 (-1.54%) As of 06/26/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Autolus Therapeutics Stock (NASDAQ:AUTL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Autolus Therapeutics alerts:Sign Up Key Stats Today's Range$1.59▼$1.6750-Day Range$1.41▼$1.8752-Week Range$1.18▼$2.70Volume765,841 shsAverage Volume1.20 million shsMarket Capitalization$432.51 millionP/E RatioN/ADividend YieldN/APrice Target$8.75Consensus RatingModerate Buy Company Overview Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications. The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma. Additional clinical and preclinical programs address targets such as BCMA in multiple myeloma and solid tumor antigens, as well as novel constructs aimed at improving T cell persistence and tumor microenvironment penetration. Autolus collaborates with academic institutions and research partners to advance its pipeline and validate emerging technologies. Founded in 2014 as a spin-out from University College London, Autolus is headquartered in London, U.K., with operational sites in the United States and Europe to support clinical trials and manufacturing scale-up. The company is led by Chief Executive Officer Christian Itin, whose background in cell therapy and immuno-oncology guides a leadership team of experienced industry executives and scientific experts. Autolus is committed to expanding global access to its therapies through regulatory filings and strategic partnerships in key markets.AI Generated. May Contain Errors. Read More Autolus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreAUTL MarketRank™: Autolus Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 433rd out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAutolus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 2 strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAutolus Therapeutics has a consensus price target of $8.75, representing about 438.5% upside from its current price of $1.63.Amount of Analyst CoverageAutolus Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Autolus Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Autolus Therapeutics are expected to grow in the coming year, from ($0.96) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Autolus Therapeutics is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Autolus Therapeutics is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAutolus Therapeutics has a P/B Ratio of 2.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Autolus Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.81% of the float of Autolus Therapeutics has been sold short.Short Interest Ratio / Days to CoverAutolus Therapeutics has a short interest ratio ("days to cover") of 10.17, which indicates bearish sentiment.Change versus previous monthShort interest in Autolus Therapeutics has recently increased by 5.39%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAutolus Therapeutics does not currently pay a dividend.Dividend GrowthAutolus Therapeutics does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.63 News SentimentAutolus Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Autolus Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for AUTL on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat Follows6 people have added Autolus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Autolus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders25.70% of the stock of Autolus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.83% of the stock of Autolus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Autolus Therapeutics' insider trading history. Receive AUTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AUTL Stock News HeadlinesAutolus Therapeutics to Participate in Upcoming Investor ConferenceJune 25 at 7:00 AM | globenewswire.comAutolus Therapeutics (AUTL) Stock Sees Split Analyst Revisions After Early Aucatyzl Launch SignalsJune 24 at 11:34 PM | finance.yahoo.comStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.June 27 at 1:00 AM | Porter & Company (Ad)Why Autolus Therapeutics (AUTL) Looks Less Speculative as AUCATZYL Revenue BuildsJune 17, 2026 | finance.yahoo.comAutolus Therapeutics Receives Prix Galien UK AwardJune 12, 2026 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Autolus Therapeutics (AUTL), Galmed Pharmaceuticals (GLMD) and Oculis Holding (OCS)June 11, 2026 | theglobeandmail.comHow The Autolus Therapeutics (AUTL) Investment Story Is Evolving With A Steady Analyst OutlookJune 7, 2026 | finance.yahoo.comAutolus Therapeutics to Participate in Upcoming Investor ConferencesMay 27, 2026 | globenewswire.comSee More Headlines AUTL Stock Analysis - Frequently Asked Questions How have AUTL shares performed this year? Autolus Therapeutics' stock was trading at $1.99 at the start of the year. Since then, AUTL stock has decreased by 18.3% and is now trading at $1.6250. How were Autolus Therapeutics' earnings last quarter? Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) issued its quarterly earnings results on Friday, May, 15th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.02. The firm earned $26.22 million during the quarter, compared to the consensus estimate of $26.27 million. Autolus Therapeutics had a negative net margin of 311.98% and a negative trailing twelve-month return on equity of 128.59%. Read the conference call transcript. When did Autolus Therapeutics IPO? Autolus Therapeutics (AUTL) raised $141 million in an initial public offering (IPO) on Friday, June 22nd 2018. The company issued 8,823,530 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers. Who are Autolus Therapeutics' major shareholders? Top institutional investors of Autolus Therapeutics include Renaissance Technologies LLC (0.86%), Bank of America Corp DE (0.69%), Cetera Investment Advisers (0.42%) and Aubrey Capital Management Ltd (0.05%). How do I buy shares of Autolus Therapeutics? Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Autolus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Autolus Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and Company Calendar Last Earnings5/15/2026Today6/27/2026H.C. Wainwright 4th Annual Cell Therapy Virtual Conference6/30/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 3 weeks, AUTL's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AUTL CIK1730463 Webwww.autolus.com Phone442038296230FaxN/AEmployees330Year Founded2014Price Target and Rating Average Price Target for Autolus Therapeutics$8.75 High Price Target$10.00 Low Price Target$5.00 Potential Upside/Downside+438.5%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$287.53 million Net Margins-311.98% Pretax Margin-311.32% Return on Equity-128.59% Return on Assets-46.25% Debt Debt-to-Equity RatioN/A Current Ratio5.80 Quick Ratio5.28 Sales & Book Value Annual Sales$75.39 million Price / Sales5.74 Cash FlowN/A Price / Cash FlowN/A Book Value$0.67 per share Price / Book2.43Miscellaneous Outstanding Shares266,160,000Free Float197,754,000Market Cap$432.51 million OptionableOptionable Beta2.02 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free Report This page (NASDAQ:AUTL) was last updated on 6/27/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...Behind the Markets | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredElon’s new "tollbooth"The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
